首页> 美国卫生研究院文献>HemaSphere >HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

【2h】

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

机译：HOVON110 / ReBeL研究：来那度胺利妥昔单抗联合或不联合苯达莫司汀治疗复发/难治性滤泡性淋巴瘤患者的随机I / II期I / II期研究结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 HemaSphere
作者
Wendy B.C. Stevens; Katerina Bakunina; Marloes Cuijpers; Martine Chamuleau; Aart Beeker; Rob Fijnheer; Holger Hebart; Hein P.J. Visser; Jeanette K. Doorduijn; Kim Linton; Martin Dreyling; Daphne de Jong; Marie José Kersten;
展开▼
作者单位

展开▼
年(卷),期 2020(4),1
年度 2020
页码 -1
总页数 3
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine plus Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data [J] . Zinzani Pier Luigi, Topp Max S., Yuen Sam L. S., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：venetoclax plus rituximab或随机化血红蛋白加上苯甲蛋白（Br）与Br复发/难治性滤泡淋巴瘤患者的阶段2研究：临时数据
2. AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R-2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma [J] . Leonard John P., Trneny Marek, Izutsu Koji, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：增强：复发/难治性惰性非霍奇金淋巴瘤患者的Lenalidomide Plus Rituximab（R-2）Vs Rituximab（R-2）的III期随机研究
3. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. [J] . Fowler N, Kahl BS, Lee P, Journal of Clinical Oncology . 2011,第25期

机译：复发或难治性滤泡性淋巴瘤患者中的硼替佐米，苯达莫司汀和利妥昔单抗：II期垂直研究。
4. Efficacy Analysis of Preservative-Free Tafluprost and Timolol in Open-Angle Glaucoma and OHT Patients in a Phase-III Study [C] . GrundenJ., Lupinacci R. International Symposium on Ocular Pharmacology and Therapeutics . 2013

机译：在第三阶段研究中，在开放角度荧光眼和OHT患者中无防腐型TaFluprost和蒂莫尔的疗效分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Response‐adapted treatment with rituximab bendamustine mitoxantrone and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial [O] . Francisco‐Javier Peñalver, José‐Antonio Márquez, Soledad Durán, 2019

机译：一线免疫化疗后复发或难治性滤泡性淋巴瘤患者应用利妥昔单抗苯达莫司汀米托蒽醌和地塞米松进行适应性治疗然后进行利妥昔单抗维持：RBMDGELTAMO08 II期试验的结果
7. HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma [O] . Wendy B.C. Stevens, Katerina Bakunina, Marloes Cuijpers, 2020

机译：Hovon110 / Rebel学习：I / II的一部分的结果是Lenalidomide，Rituximab的随机阶段I / II研究，其中有或没有弯曲的复发/难治性滤泡淋巴瘤的患者

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

著录项

相似文献

相关主题

期刊订阅